Filing Details

Accession Number:
0001209191-14-021131
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-03-17 20:00:31
Reporting Period:
2014-03-17
Filing Date:
2014-03-17
Accepted Time:
2014-03-17 20:00:31
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1001233 Sangamo Biosciences Inc SGMO Biological Products, (No Disgnostic Substances) (2836) 680359556
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1234386 Ii O Edward Lanphier C/O Sangamo Biosciences Inc.,
Point Richmond Tech Cntr, 501 Canal Blvd
Richmond CA 94804
President & Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-03-17 50,000 $5.19 345,000 No 4 M Direct
Common Stock Disposition 2014-03-17 50,000 $23.22 295,000 No 4 S Direct
Common Stock Disposition 2014-03-10 4,000 $0.00 1,591,054 No 4 G Indirect By Trust
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 G Indirect By Trust
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (Right to Buy) Disposition 2014-03-17 50,000 $0.00 50,000 $5.19
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2014-12-19 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 100,000 Indirect By Trust for Daughter
Footnotes
  1. Includes 100,000 shares, 120,000 shares, and 75,000 shares subject to restricted stock units granted on December 8, 2011, December 6, 2012, and December 12, 2013, respectively, that will be issued as such units vest in accordance with their terms.
  2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2013.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.99 to $23.50, inclusive. The Reporting Person undertakes to provide to Sangamo BioSciences, Inc., any security holder of Sangamo BioSciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
  4. These shares are held in the Lanphier Trust.
  5. The Reporting Person disclaims beneficial ownership of the shares held by his child and this report shall not be deemed to be an admission that Mr. Lanphier is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
  6. All shares underlying this option are vested and immediately exercisable, and such option will expire on December 19, 2014.